Peek Behind the Paper: cheaper but challenging biosimilars

In this feature, we speak with study author Pinar Karaca-Mandic (University of Minnesota, MN, USA) about the article discussing the potential benefits biosimilars may confer, as well as the additional regulatory challenges associated with these drugs. Biosimilars are near identical agents of biologic products, offering matched drug safety and efficacy and generating competition between drug producers, which can reduce drug costs. In 2019, we reported on the results of a new analysis, conducted by researchers from the University of Minnesota and Mayo Clinic (both MN, USA), suggesting that the cost savings offered by biosimilars are not always so uniform and substantial. Further, biosimilars...